Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the second quarter and first half 2020 on Thursday, 27 August 2020 . A presentation by the Nordic Nanovector’s senior management team will take place the same day at 8:30 am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo, Meeting Room:
| OSLO, Norway, Aug. 21, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the second quarter and first half 2020 on Thursday, 27 August 2020. A presentation by the Nordic Nanovector’s senior management team will take place the same day at 8:30 am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo, Meeting Room: Vika Auditorium. The presentation will be a live webcast, and a recording will then be available at www.nordicnanovector.com in the section: Investors & Media. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020 from 7:00 am CEST the same day. For further information, please contact: IR enquiries Malene Brondberg, CFO Media Enquiries Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson) About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets. This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector | ||
Company Codes: Bloomberg:NANO@NO, ISIN:NO0010597883, Oslo:NANO, RICS:NANO.OL |
View original content:
